BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19127250)

  • 1. Enhanced factor VIII heavy chain for gene therapy of hemophilia A.
    Chen L; Lu H; Wang J; Sarkar R; Yang X; Wang H; High KA; Xiao W
    Mol Ther; 2009 Mar; 17(3):417-24. PubMed ID: 19127250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene.
    Ishiwata A; Mimuro J; Kashiwakura Y; Niimura M; Takano K; Ohmori T; Madoiwa S; Mizukami H; Okada T; Naka H; Yoshioka A; Ozawa K; Sakata Y
    Thromb Res; 2006; 118(5):627-35. PubMed ID: 16371232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene.
    Chen L; Zhu F; Li J; Lu H; Jiang H; Sarkar R; Arruda VR; Wang J; Zhao J; Pierce GF; Ding Q; Wang X; Wang H; Pipe SW; Liu XQ; Xiao X; Camire RM; Xiao W
    Mol Ther; 2007 Oct; 15(10):1856-62. PubMed ID: 17653101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype.
    Sarkar R; Tetreault R; Gao G; Wang L; Bell P; Chandler R; Wilson JM; Kazazian HH
    Blood; 2004 Feb; 103(4):1253-60. PubMed ID: 14551134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient production of dual recombinant adeno-associated viral vectors for factor VIII delivery.
    Wang Q; Dong B; Firrman J; Roberts S; Moore AR; Cao W; Diao Y; Kapranov P; Xu R; Xiao W
    Hum Gene Ther Methods; 2014 Aug; 25(4):261-8. PubMed ID: 25093498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette.
    Lu H; Chen L; Wang J; Huack B; Sarkar R; Zhou S; Xu R; Ding Q; Wang X; Wang H; Xiao W
    Hum Gene Ther; 2008 Jun; 19(6):648-54. PubMed ID: 18500941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII.
    Scallan CD; Liu T; Parker AE; Patarroyo-White SL; Chen H; Jiang H; Vargas J; Nagy D; Powell SK; Wright JF; Sarkar R; Kazazian HH; McClelland A; Couto LB
    Blood; 2003 Dec; 102(12):3919-26. PubMed ID: 12893764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced plasma factor VIII activity in mice via cysteine mutation using dual vectors.
    Zhu F; Liu Z; Miao J; Qu H; Chi X
    Sci China Life Sci; 2012 Jun; 55(6):521-6. PubMed ID: 22744182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors.
    Sabatino DE; Lange AM; Altynova ES; Sarkar R; Zhou S; Merricks EP; Franck HG; Nichols TC; Arruda VR; Kazazian HH
    Mol Ther; 2011 Mar; 19(3):442-9. PubMed ID: 21081906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.
    Biswas M; Palaschak B; Kumar SRP; Rana J; Markusic DM
    Front Immunol; 2020; 11():1293. PubMed ID: 32670285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice.
    Sarkar R; Mucci M; Addya S; Tetreault R; Bellinger DA; Nichols TC; Kazazian HH
    Hum Gene Ther; 2006 Apr; 17(4):427-39. PubMed ID: 16610930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AAV-based neonatal gene therapy for hemophilia A: long-term correction and avoidance of immune responses in mice.
    Hu C; Lipshutz GS
    Gene Ther; 2012 Dec; 19(12):1166-76. PubMed ID: 22241178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Codon optimization of human factor VIII cDNAs leads to high-level expression.
    Ward NJ; Buckley SM; Waddington SN; Vandendriessche T; Chuah MK; Nathwani AC; McIntosh J; Tuddenham EG; Kinnon C; Thrasher AJ; McVey JH
    Blood; 2011 Jan; 117(3):798-807. PubMed ID: 21041718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
    Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
    Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term correction of hemorrhagic diathesis in hemophilia A mice by an AAV-delivered hybrid FVIII composed of the human heavy chain and the rat light chain.
    Mao J; Wang Y; Zhang W; Shen Y; Zhang G; Xi W; Wang Q; Ruan Z; Wang J; Xi X
    Front Med; 2022 Aug; 16(4):584-595. PubMed ID: 35038106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial correction of murine hemophilia A with neo-antigenic murine factor VIII.
    Sarkar R; Gao GP; Chirmule N; Tazelaar J; Kazazian HH
    Hum Gene Ther; 2000 Apr; 11(6):881-94. PubMed ID: 10779165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice.
    Greig JA; Wang Q; Reicherter AL; Chen SJ; Hanlon AL; Tipper CH; Clark KR; Wadsworth S; Wang L; Wilson JM
    Hum Gene Ther; 2017 May; 28(5):392-402. PubMed ID: 28056565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.
    Nguyen GN; George LA; Siner JI; Davidson RJ; Zander CB; Zheng XL; Arruda VR; Camire RM; Sabatino DE
    J Thromb Haemost; 2017 Jan; 15(1):110-121. PubMed ID: 27749002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
    Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
    Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.